Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Letter

Bcl-xL affects the development of functional CD4 Tregs

Amir Sharabi12* and Edna Mozes1

Author Affiliations

1 Department of Immunology, The Weizmann Institute of Science, 240 Hertzl Street, Rehovot 76100, Israel

2 Department of Internal Medicine B, The Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel. Published: 23 July 2010

For all author emails, please log on.

Arthritis Research & Therapy 2010, 12:405  doi:10.1186/ar3076


See related research by Haque et al., http://arthritis-research.com/content/12/2/R66

Published: 23 July 2010

First paragraph (this article has no abstract)

We read with great interest the article by Haque and colleagues [1] in a recent issue of Arthritis Research & Therapy. They hypothesized that co-transduction of CD4+ T cells with both forkhead box P3 transcription factor (FoxP3) and Bcl-xL will generate highly reactive regulatory T cells (Tregs) that can be used to prevent auto immune disease. The authors showed that the accumulation, persistence, and efficient function of Tregs were attributable to the expression of Bcl-xL in CD4 Tregs.